Search Results
Search results for "Glaxo Inc"
Results found for "Glaxo Inc"
- Purpose-Driven Opioid Research: Catherine Demeryâs Academic Path
âTheyâve seen a 30 to 60 percent increase in the number of fentanyl samples that contain xylazine in Her next steps include using floxed mouse models  and viral tools  to dissect the downstream pathways
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
between Eli Lilly and Novo Upcoming events: Â September GPCR symposia across Europe, UK, and onlineâincluding FAQ: Premium Membership đš Whatâs included?
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
Must-read publications: Â Stay updated on cutting-edge research, including the potentiation of GPCR signaling Threat Avoided: Â Prevent costly late-stage failures by incorporating kinetic modeling early in your pipeline FAQ: Premium Membership đš Whatâs included?
- Fluorescence Polarization in GPCR Research
readers are usually available in regular laboratories, although not all have FP filters, they are usually included Reference compounds XAC, ISVY-130, and MRS 1220 were included as standard AâAR antagonists. 2.     Â
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
Yet fentanyl is increasingly not alone.
- Why âDisplacementâ Misleads You: Allosteric Binding Demystified
When a PAM increases radioligand binding but suppresses functional response, itâs not broken pharmacologyâit
- Advantages of Fluorescent Probes in GPCR Assays
limitations, especially safety concerns, low temporal resolution and the need for specialized facilities including Our portfolio also includes all kinds of dyes, such as pharmacophores conjugated to near-infrared fluorophores Once the cells are ready, the fluorescent ligand is added, and the cells are incubated with it for a After incubation, cells are observed using a confocal microscope. Celtarysâ protocol section includes detailed protocols for diverse applications and fluorescent ligands
- Mariaâs Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Wendy Youngâs talk, during session 3 on day 2, was also incredible.
- Differential binding of Î9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)
Cannabinoids have the potential to treat a variety of diseases, including neurological and metabolic The curves were obtained using 100nM of probe and increasing concentrations of Î9-THC, Î9-THCA and Î9
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
when talking about SCRAs (Synthetic Cannabinoid Agonists), as one of the series developed by Pfizer, including Tag-LiteÂŽÂ competition binding curves were obtained by using 100 nM of CELT-335 and increasing concentrations Competition binding curves were obtained through Tag-liteÂŽÂ technology using 10 nM of CELT-335 and increasing For further validation, a larger range of compounds will be tested, including screening chemical libraries
- Radioligands vs. Fluorescent Ligands: Binding Assays
While their high specificity and extensive experience working with them, other drawbacks include radiation
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
temporary therapeutic effects.[3,4]Â Since dopaminergic signaling is very complex, thereâs a need to increase FA of 3Â nM (orange squares) or 0.5Â nM (blue circles) CELT-419 were measured after 2Â h incubation with Change in FA level was measured after incubation of 0.5Â nM CELT-419, 1Â ÎźL BBV/well (CD3RÂ = 0.7Â nM), and HEK293-D3RÂ cells in DMEM medium with added 9% FBS and antibiotic antimycotic solution were incubated As the next step, the cells were incubated with different concentrations of CELT-419 to determine its
- Conjugation Strategies for Probe Development
Itâs reversible under non-reducing conditions. [ 4]   Other strategies include click chemistry,  more Thereâs no need for any catalysts; all reagents will be incorporated in the structure of the final compound
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
Learn to tie your program's progress directly to your funding runway, incorporating crucial early commercial
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Career opportunities: Â A curated list of new positions, including a Research Associate, a Senior Research misinterpreting your data by understanding how slow-offset kinetics can mimic classical patterns, leading to incorrect FAQ đš Whatâs included?
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Each subscription includes: Weekly deep dives from Dr.
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
residence timeânot potencyâpredicts therapeutic coverage â Insight into cryptic intracellular GPCR sites, including And intracellular targets, including allosteric sites unreachable from the extracellular side, become
- Your GPCR Program Decisions Depend on Good Data Interpretation
Ingo Hartung : State-of-the-art design of small molecule drugs, including PROTACs Dr. FAQ: Whatâs Included, Who Itâs For, Why Now Whatâs included?
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
GPCR Premium đš Whatâs included?
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
GPCR Premium Whatâs included? Â
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
alerts, job opportunities, and insider commentaryâall designed to help you move faster and smarter in an increasingly GPCR Premium gives you an edge in a fast-moving field. đš Premium Membership FAQ đš Whatâs included?
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
He was tasked with building an in vitro pharmacology group from scratch , including infrastructure, hiring
- Unlock the Hidden Complexity Behind GPCRsâFrom Terry Kenakinâs Vault
studying GPCRsâarguably the most important drug targets in pharmacologyâhas been wrong⌠or at least, incomplete
- Signals in Motion: Pain, Metabolism & Terryâs Corner
Meanwhile, incretin and amylin-based therapies are reshaping the obesity drug landscape.
- Pharmacology Isn't What You ThinkâIt's So Much More
Whether you're heading into your first assay or trying to make sense of inconsistent data, Terry gives
- Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools
GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr
- Knowing When to Walk, Knowing When to Run: Lessons from the Bench
A tenfold increase in methadone efficacy using PAMs.
- Science Needs Rigor, But Also Joy
But every day also includes squirrel-themed trivia and impromptu debates about obscure molecules.
- Ben Clements on Rescuing Opioids with GPCR Modulators
Redefining Opioid Pharmacology Ben and his colleagues discovered that PAMs can dramatically increase In fact, one of their recent neuroma pain studies showed a tenfold increase in methadone potency. Thatâs not an incremental advance; thatâs a potential paradigm shift. Using PAMs, his team aims to re-sensitize these conditions to opioids without increasing toxicity.
- Mapping Motion: Intermediate States, Deorphanization & Discovery
This course is included with your Premium membership. Â Access the Course Dr. These on-demand sessions are included with your Premium membership. Â






























